Abbott Receives FDA Complete Response Letter for Pain Drug
Posted on: Tuesday, 21 October 2008, 09:00 CDT
US-based healthcare company Abbott Laboratories has received a complete response letter from the FDA for its new drug application for a controlled-release form of hydrocodone with acetaminophen.
Abbott is evaluating the FDA complete response letter. The company said that it will discuss the letter with the FDA and will provide an update when appropriate.
Abbott is seeking the approval of controlled-release hydrocodone with acetaminophen as the first extended release medication in the class to provide extended relief over 12 hours; currently available short-acting hydrocodone and acetaminophen medications must be taken every four to six hours.
Source: Datamonitor
Related Articles
- New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
- Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)
- IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options
- FDA Issues Approvable Letter for Noven's Stavzor
- FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
- Merck Responds to FDA-Issued Approvable Letters for Arcoxia(R) (Etoricoxib)
- FDA Issues Approvable Letter to Cellegy Pharmaceuticals for Cellegesic(R)
- IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
- FDA Issues Warning Letter to Guidant
Rating: 3.1 / 5 (8 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds